Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Predicting recurrence in patients with stage II and III colon cancer: Validation cohort and long-term follow-up of the experimental cohort.
Authors
David Viñal
Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain;
David Viñal , Daniel Martinez-Perez , Sergio Martínez-Recio , Laura Gutiérrez-Sainz , Iciar Ruiz-Gutierrez , Diego Jiménez-Bou , Jesus Peña-Lopez , Maria Alameda-Guijarro , Gema Martin-Montalvo , Antonio Rueda-Lara , Andrea Garcia-Leal , Patricia Zwisler , Maria Elena Palacios , Ana B. Custodio , Jaime Feliu , Nuria Rodriguez Salas , Ismael Ghanem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 215)
DOI
10.1200/JCO.2023.41.4_suppl.215
Abstract #
215
Poster Bd #
L17
Abstract Disclosures
Similar Posters
First Author: Lucy Gately
Poster
2012 ASCO Annual Meeting
Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox).
First Author: Michael O'Connell
Poster
2023 ASCO Annual Meeting
The number of lymph nodes examined as a poor prognosis factor in stage II and stage III colon cancer patients undergoing curative surgery.
First Author: JEONGSEOK JEON
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Prognostic value of tumor budding in patients with stage II and III colon cancer: A single-institution experience.
First Author: David Viñal